| Name | Title | Contact Details |
|---|
InSight is the leading national telepsychiatry service provider organization with a mission to transform access to behavioral health care through innovative applications of technology. InSight has 20 years of experience with telepsychiatry and services hundreds of organizations across the nation with its on-demand, scheduled, connected services and Inpathy divisions.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.
Formed by revenue cycle industry leaders, Currance is a Rev-Cycle Performance solutions company focused on empowering community providers, physician practices and healthcare systems to achieve and sustain yield performance improvement. Currance`s strategy of Performance Partnering supports your own team by offering everything needed to drive yield performance: an intelligent technology platform that integrates with existing systems, tailored solutions, and professional services for operationalizing the technology and sustaining exceptional results. The Currance approach encompasses best-in-class knowledge of revenue cycle management, proprietary technologies, and the proven ability to engage, train, and mentor employees, adding value to clients` organizations. We embrace a mindset rooted in science and operational experience, enabling highly efficient processes and precise workflow design that improve profitability and help build patient-centered, high-performing organizations.
Chartered Health Plan/DC HealthCare Alliance is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Universal Health Care Group is a Saint Petersburg, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.